Actinogen locks XanaMIA database, topline results due mid-November
Actinogen Medical has confirmed database lock in its XanaMIA trial of oral Xanamem (emestedastat) in Alzheimer's disease, narrowing its guidance for topline results to mid-November 2026, from the previously stated broad "November" window. The ASX-listed Sydney biotech said the milestone keeps the programme firmly on schedule.
XanaMIA is a randomised, double-blind, placebo-controlled Phase 2b/3 study evaluating Xanamem 10 mg against placebo over 36 weeks in 247 participants recruited across Australia and the United States. Participants were selected using elevated plasma pTau181 as a pre-screening biomarker, a relatively accessible measure that Actinogen says correlates strongly with confirmed Alzheimer's pathology and selects for individuals with a more progressive disease course. The company argues this design increases statistical power to detect a treatment effect, and mirrors the Phase 2a population in which a meaningful benefit was observed in a 2024 publication by Taylor et al.
The science behind Xanamem
Xanamem works by inhibiting 11beta-HSD1, the enzyme responsible for synthesising cortisol in brain tissue. The mechanism is distinct from current approved Alzheimer's therapies, which predominantly target amyloid or tau directly. Chronically elevated brain cortisol has been associated with neuronal toxicity and disease progression in Alzheimer's, and the hippocampus, a region central to memory, expresses high levels of 11beta-HSD1. Actinogen describes Xanamem as the only known 11beta-HSD1 inhibitor capable of efficiently crossing the blood-brain barrier and modulating regional cortisol levels.
Alongside the trial update, a new academic manuscript examining the role of cortisol in central nervous system diseases, including Alzheimer's and major depressive disorder, has been accepted for pre-publication in the peer-reviewed journal Clinical and Translational Neuroscience. The paper sets out the scientific rationale for targeting tissue cortisol synthesis in the brain, lending independent academic weight to Actinogen's platform thesis.
Chief executive Steven Gourlay said positive results in November "would clearly establish brain cortisol control as an important and treatable part of the biology of Alzheimer's disease." He added that the company was grateful to all patients, families and clinical staff who contributed to the trial.
Market context and competitive landscape
Alzheimer's drug development has seen renewed commercial and scientific momentum following the approvals of the anti-amyloid antibodies lecanemab and donanemab in the United States. However, those therapies require infusion and carry well-documented risks of amyloid-related imaging abnormalities. An oral, once-daily agent with a distinct cortisol-targeting mechanism would occupy a meaningfully different profile should XanaMIA data prove positive, and could be positioned as complementary to rather than competitive with the amyloid class.
The broader 11beta-HSD1 inhibition field has had a difficult history in metabolic disease, where multiple programmes from larger pharma groups failed to show sufficient benefit. Actinogen's thesis rests on the brain-specific pharmacology of Xanamem and its biomarker-enriched trial design. An Independent Data Monitoring Committee conducted an interim futility and safety analysis in January 2026 and recommended the trial continue to completion, a meaningful, if not definitive, positive signal.
Xanamem is not approved by the FDA or any global regulator and remains an investigational product. With topline data weeks away, the mid-November readout will be one of the more closely watched late-stage Alzheimer's catalysts of the year.